Navigation Links
Reducing off-label use of antipsychotic medications may save money
Date:5/15/2012

Reducing the non-FDA-approved use of antipsychotic drugs may be a way to save money while having little effect on patient care, according to a Penn State College of Medicine study.

Researchers say that 57.6 percent of patients prescribed antipsychotic medications in data from 2003 did not have schizophrenia or bipolar disorder, the conditions for which the drugs were approved for use. Use of medication for treatments that is not FDA-approved is called off-label use.

"Given healthcare reform and widespread crisis in state revenues, state Medicaid programs will be under pressure to serve larger patient populations, increasing their fiscal stress," said Douglass L. Leslie, Ph.D., professor of public health sciences. "Medicaid prescription drug programs covered 75 percent of all antipsychotic prescription medications in the United States in 2002. Reducing off-label antipsychotic use may generate savings with little impact on patient outcomes."

Researchers looked at data for 42 states from 2003, the latest data available at the time of analysis, from the Centers for Medicare & Medicaid Services. They report their results in a recent issue of American Journal of Managed Care. Patients in a Medicaid fee-for-service plan for the entire year were chosen using de-identified patient information that could not be traced to the individuals. The researchers chose patients without a diagnosis of either schizophrenia or bipolar disorder during 2003 who received an antipsychotic medication.

During 2003, 372,038 patients received an antipsychotic medication. Of these patients, 214,113, or 57.6 percent, did not have a diagnosis of schizophrenia or bipolar disorder. Diagnoses included other mental disorders: 35 percent, minor depression -- 25.4 percent, major depression -- 23.2 percent, no mental disorder -- 18.8 percent, conduct disorder -- 18.8 percent, and anxiety disorder -- 16.2 percent.

"A high rate of off-label antipsychotic use would not necessarily be of concern if there were scientific evidence supporting the effectiveness of these medications for conditions other than schizophrenia and bipolar disorder," Leslie said.

Off-label use is supported in the medical community, with the American Academy of Neurology endorsing the use of quinine for treatment-resistant leg cramps, for example. Since 2003, some of the antipsychotic medications have been approved by the FDA for the treatment of other conditions, including irritability in autism and treatment-resistant depression. However, at the time the data were collected they were considered off-label.

The rate of off-label use of antipsychotics is high compared to other medications. Other studies have shown off-label medication use includes cardiovascular drugs: 46 percent, anticonvulsants -- 46 percent, and antiasthmatics -- 42 percent.

"Antipsychotics were the highest selling medication class at $14.6 billion in 2009," Leslie said. "Medicaid bears a significant proportion of these costs. Hence, off-label use may be responsible for a considerable portion of state Medicaid budgets, with little or no documented clinical benefit and a substantial risk of adverse effects. Off-label use may be an area of potential savings with little impact on patient outcomes."

The newest antipsychotic drugs can cost up to $10 per day at doses recommended for patients with schizophrenia.

According to the researchers, more research is needed to determine if off-label use of antipsychotic medications yields substantial clinical benefit and to identify how doctors decide to prescribe these drugs for non-FDA approved conditions.

Reasons why drugs may be prescribed off-label include a lack of research results showing the drug's effectiveness in certain patients or for other conditions, or that the drugs may be used as a last resort for those patients who have not responded to other treatments. Further research is needed on the decision-making process of doctors to prescribe off-label.

"Where there is limited evidence of clinical benefit, greater caution should probably be used before prescribing these drugs off-label because they can have hazardous side effects," Leslie said.


'/>"/>

Contact: Matthew Solovey
msolovey@hmc.psu.edu
717-531-8606
Penn State
Source:Eurekalert

Related medicine news :

1. Reducing post-traumatic stress after ICU
2. Researchers determine vitamin D blood level for reducing major medical risks in older adults
3. American Cancer Society report finds continued progress in reducing cancer mortality
4. Ruxolinitib better at reducing myelofibrosis symptoms, study shows
5. AIDS Research Holds Promise for Reducing HIV Transmission Rates
6. Diabetes drug shows promise in reducing risk of cancer
7. Lancet pneumonia study offers new hope for reducing No. 1 cause of child death
8. SIRT(ain) benefit of reducing calories
9. Apixaban superior to warfarin for preventing stroke, reducing bleeding and saving lives
10. Chinese Herbs Equal to Tamiflu in Reducing H1N1 Fever: Study
11. American Cancer Society report finds continued progress in reducing cancer mortality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:1/16/2017)... Grants Pass, OR (PRWEB) , ... January 16, ... ... Kent Heckenlively, author, editor, attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, ... and attorney Kent Heckenlively to her nationally syndicated radio program, The Sharon Kleyne ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all ... but to test for, as well. The money spent screening for and treating cancer ... the U.S. screen patients for cancer more than in any other country that has ...
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been selected ... 100 organizations honored for their accomplishments in the field of midmarket financial software. , ... and recognition, and innovation. Selection is not based on revenue and those firms chosen ...
(Date:1/15/2017)... NC (PRWEB) , ... January 15, 2017 , ... Whole Health Supply, LLC is announcing ... . There are also new avenues for purchase. , The 2017 edition has wide ... cause issues for the older boomers as well as diabetics. This handle is reinforced for ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... YORK , Jan. 17, 2017 Immune ... stage biopharmaceutical company, announced today that it will hold ... Symposium on Acute Leukemias (ISAL) XVI in ... is entitled:  "Reinforcing the Efficacy of Immunotherapy for the ... take place on Monday February 20 th , 2017 from ...
(Date:1/17/2017)... , Jan. 17, 2017  Zimmer Biomet Holdings, Inc. ... healthcare , today announced that it has ... strength of the Zimmer Biomet management team. Effective ... will assume the position of President, Americas and ... Delp previously served as Zimmer Biomet,s Vice President ...
(Date:1/17/2017)... LONDON , January 17, 2017 ... poised to potentially earn millions in revenue with the ... prevent massive numbers of strokes with a simple test ... Biotech Companies with latest developments in the markets today ... PLC (NYSE: AZN ), Cancer Genetics, Inc. ...
Breaking Medicine Technology: